Background: Drug shortages require clinical teams to decide how to allocate drugs in limited supply among their patients. Ethical frameworks are invaluable for promoting rational approaches to drug distribution, but gaps remain between ethical theory and clinical application. The goal of this work was to explore how decision modeling could supplement ethical frameworks to inform drug distribution from the perspective of a clinical team.
INTRODUCTION
Drug shortages have challenged all aspects of the medical community for the past decade. [1] [2] [3] [4] By definition, supply during a shortage is inadequate to meet demand and patients with legitimate needs may be unable to receive their intended medication. 5 Deciding which patients will not receive the medication in short supply is often left to medical teams and hospital systems. Such decisions raise significant ethical issues and have been the focus of proposed ethical frameworks [6] [7] [8] [9] [10] that are invaluable for promoting rational approaches to drug Abbreviations: ATRT, atypical teratoid rhabdoid tumor; BSA, body surface area; CNS, central nervous system; HR-ALL, high-risk acute lymphoblastic leukemia; IT, intrathecal; Mg/LYS, milligrams per life year saved; MTX, methotrexate; OS, osteosarcoma; SR-ALL, standard risk acute lymphoblastic leukemia allocation. Gaps remain, however, between ethical theory and clinical application. Medical teams must consider complex objective information about patients, treatments, and potential outcomes as well as ethical frameworks to make treatment priorities.
Decision modeling and analysis has been used to supplement ethical frameworks to optimize allocation of other medical resources in limited supply such as organ transplants. 11, 12 This method compares the input per outcome (i.e., efficiency or utility) across possible uses of the limited resource with the aim to maximize utility across the choices. In the following analysis, we applied decision modeling to a hypothetical drug shortage scenario for methotrexate (MTX), a chemotherapy agent used in the treatment of a variety of pediatric and adult cancers. This analysis is from the perspective of a single institution. We began with three principles of how our hypothetical medical team would like to (2) treat all patients with the same diagnosis and treatment plan equally, and (3) consider an entire course of treatment when accounting for a patient's need. 6 After confirming that all patients could not be treated under our shortage scenarios, we tested alternative and substitution strategies to optimize distribution.
METHODS
We developed a hypothetical scenario wherein a pediatric oncology clinic had access to 50,000 mg of MTX for the foreseeable future. We Probabilities of tumor responses to MTX were obtained from the literature associated with each regimen or diagnosis and supplemented by expert opinion ( Table 2 ). The amount of MTX included in each treatment strategy was the dose required to treat an average-sized patient based on desired dose per square meter times BSA. To calculate remaining years to live after diagnosis, we first used life expectancy tables to estimate the remaining years to live for a person without childhood cancer at the average age at presentation for each diagnosis. 20 Because survivors of childhood cancer have a myriad of late complications associated with early mortality, we subtracted years of life for the impact of cancer and treatment by converting diseasebased standard mortality ratios 21 into years using a factor of 0.1373, as suggested by Lai et al. 22 We assumed that if initial treatment failed but subsequent therapy resulted in a tumor response, the number of years of life lost due to cancer and treatment would double. If both initial and subsequent therapy failed, we estimated a life expectancy of 5 years, except for the patient receiving phase I therapy for whom we estimated 0.5 years. We applied an annual discount factor of 3% to both costs and outcomes. 23 We ranked the treatments in order of treatment efficiency by least to greatest mg/LYS. The robustness of the model was tested under various conditions. Discounting was applied to costs and outcomes independently. We limited the outcome of life expectancy after survival to 10 years to negate the impact on LYS of a longer life expected by a younger child. Finally, we varied survival probabilities to extremes of confidence intervals. When no confidence interval was available, we assigned a standard deviation of 20% of the estimate. 24 To optimize our MTX allocation, we evaluated substituting lower dose treatment regimens or removing MTX. For each potential substitution, we considered the incremental changes in individual patient outcomes and allocation across our population associated with alternative dosing strategies whenever data were available. To assess the potential clinical impact of substituting a less effective treatment strategy, we calculated the difference in number of patients who would be expected to have a worse outcome if 100 patients received each potential treatment using the following formula:
Expected no. of children with worse outcome if 100 children were treated with treatment A versus B = (probability of event-free survival treatment A × 100) − (probability of event-free survival treatment B × 100)
Finally, we calculated the total number of patients who could be treated using each allocation strategy. (Fig. 2) .
RESULTS
Ranking the regimens in order of most to least efficient use of MTX as determined by decision modeling is presented in Table 3 . system, the ability to treat patients is no different than the previously described first-come-first-served distribution with patients skipped if a full treatment course could not be given (Fig. 2) . Furthermore, changing the order of treatment according to the model limitations identified in the sensitivity analysis does not change the possibility of who could receive treatment because there is no possible combination that would allow both children with HR-ALL and the child with OS to receive full-dose MTX when only 50,000 mg is available.
Treatment substitutions
For each regimen, we explored how alternative dosing or elimination of the drug from the regimen would affect the individual patients and distribution of drug.
IT: CNS leukemia prophylaxis with IT MTX alone or in combination with cytarabine and hydrocortisone has been an established practice for lymphoid malignancies since the 1980's. 25 If inadequate quantities of MTX were available to provide CNS prophylaxis, Ara-C and hydrocortisone alone could be used but no studies of efficacy have been per- Headstart II to MTX is controversial as the patient numbers are small F I G U R E 2 Drug distribution by ranking strategy. First-come-first-served represents the order in which patients are scheduled to appear. Firstcome-first-served + skipping incorporates skipping, or not treating, the next patient in order of presentation if inadequate drug is available for that patient. Efficiency represents delivering drug in order of lowest to highest MTX mg/LYS. Efficiency + substitution represents efficiency incorporating substitutions for lower dose regimens when doing so allows more children to be treated and surgical resection and supportive care was better on the latter study. 26, 27 Because the evidence for including MTX in the overall treatment regimen is limited, an alternative would be to not include MTX in this child's treatment. This would save 9,280 mg, enough to treat the child with OS if the shortage of drug was 50,000 mg and the lower dose of MTX was substituted for treatment of HR-ALL. Under more stringent shortages, this omission would not affect treatment for OS.
TA B L E 3 Efficiency ranking of best practices
OS: Similar to ATRT, the inclusion of MTX in the multiagent chemotherapy and surgical control of OS derives from sequential single arm clinical trials rather than randomized studies. [28] [29] [30] Because the evidence that MTX improves outcomes for children with OS is unclear, an alternative would be to not include MTX in the OS treatment plan.
This would save 38,400 mg of MTX. If treatment were given in order of efficiency or first-come-first-served, this OS patient could not receive a full course of MTX anyway because there would be inadequate quantities of drug available.
Final ranking
Ranking regimens by MTX mg/LYS and substituting less effective reg- 
DISCUSSION
We present a method for ranking treatment regimens by efficiency recommendations. We also gave no particular weight to the patients receiving MTX as part of a clinical trial. 6, 7, 9 We limited our analysis to very broad patient definitions and treat- It is critical to face the reality that if an agent that contributes to improved outcomes is truly in short supply, no allocation scenario exists that does not result in a worse outcome for some patients. This conclusion highlights the importance of clinicians, patient advocates, and legislative groups continuing to work to minimize drug shortages. Not all choices are clear or easy, particularly when data are limited. Our hypothetical scenario clearly demonstrates, however, that first-come-first-served allocation can result in the worst outcome with the fewest patients receiving the drug and the least evidence to support their treatment. The use of decision modeling offers the potential to increase transparency and fairness in distribution and decrease anxiety for decision makers who must determine which patients will receive a limited resource.
